TransplantationApolipoprotein E2/E5 Variants in Lipoprotein Glomerulopathy Recurred in Transplanted KidneyMIYATA, TOSHIO*; SUGIYAMA, SATOSHI†; NANGAKU, MASAOMI*; SUZUKI, DAISUKE*; URAGAMI, KEN-ICHI*; INAGI, REIKO*; SAKAI, HIDETO*; KUROKAWA, KIYOSHI* Author Information *Molecular and Cellular Nephrology, Institute of Medical Sciences and Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan †Department of Nephrology, Chukyo Hospital, Nagoya, Japan. Correspondence to Dr. Toshio Miyata, Molecular and Cellular Nephrology, Institute of Medical Sciences and Department of Internal Medicine, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan. Phone: 81 463 93 1936; Fax: 81 463 93 1938; E-mail: [email protected] Received November 23, 1998. Accepted February 3, 1999. Journal of the American Society of Nephrology 10(7):p 1590-1595, July 1999. | DOI: 10.1681/ASN.V1071590 Buy Metrics Abstract Lipid abnormalities are associated with various disorders ranging from generalized atherosclerosis to renal diseases, including lipoprotein glomerulopathy that is characterized by glomerular lipoprotein thrombi and causes type III hyperlipoproteinemia, proteinuria, and renal failure. This study examines lipoprotein glomerulopathy, which recurred in a transplanted kidney. Molecular biologic analysis of the patient's apolipoprotein (apo) E gene demonstrated E2/E5 type variants. Immunohistochemical analysis of the diseased kidney demonstrated various lipid peroxidation-specific protein adducts, suggesting a potential role of oxidative stress in this disorder. Recurrence in the transplanted kidney suggested a pathogenic role of extraglomerular humoral component(s) resulting from abnormal lipoprotein metabolism, presumably linked to apo E and other genetic or acquired factor(s). Furthermore, the finding that the patient showed pathologic abnormalities in the transplanted kidney with no clinical signs or symptoms of renal disease indicated that lipoprotein glomerular damage progresses early before any clinical manifestations. Copyright © 1999 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.